Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 8Recruiting 5Unknown 2Terminated 2Not yet recruiting 2Withdrawn 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Breast 3Gastrointestinal 2Sarcoma 1NET 1Lymphoid 1Endocrine 1

Conditions

Sarcoma 1Neuroendocrine Tumors 1Lymphoma 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1

Interventions

Lenalidomide 2Cyclophosphamide 2ibrutinib 1fludarabine 1Vincristine 1Ropivacaine 1Rituximab 1R-CHOP protocol 1Prednisone 1Nivolumab 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Maintenance 1Magnetic Resonance Spectroscopy 1Leukapheresis 1JNJ-64619178 1JNJ-64264681 1Inosine Monophosphate 1Fluorodeoxyglucose F18 1Etoposide 1Educational Status 1Doxorubicin 1Decitabine 1Brentuximab Vedotin 1Blood Specimen Collection 1Biopsy, Fine-Needle 1Bendamustine Hydrochloride 1Angptl4 protein, mouse 17-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Fluorodeoxyglucose F18 × Lymphoid × Clear all
NCT05396118 2024-05-14

Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients

Rigshospitalet, Denmark

Phase 2 Enrolling by invitation
15 enrolled
BreastEndocrineLymphoidNETSarcoma

Breast Neoplasms, Lymphoma, Sarcoma, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡